期刊文献+

法舒地尔与地尔硫卓治疗心脏X综合征疗效比较 被引量:2

Comparison of fasudil and diltiazem in treating patients with cardiac X-syndrome
暂未订购
导出
摘要 目的观察应用法舒地尔与地尔硫卓治疗心脏X综合征(CSX)患者的疗效。方法49例心脏X综合征患者随机接受法舒地尔(24例)或地尔硫卓(25例)治疗,随访治疗3个月后的临床情况并复查平板运动试验、冠状动脉血流储备(CFR),以及一氧化氮(NO)、血浆内皮素-1(ET-1)的含量。结果与本组治疗前比较,用药3个月后两组胸痛例数及最大ST段压低幅度明显减少,ET-1水平明显下降,CFR及NO水平明显升高,运动总时间、ST段压低1mm时间明显延长(P〈0.01,P〈0.05)。与地尔硫卓组相比,法舒地尔组胸痛例数及最大ST段压低幅度明显减少(均为P〈0.05),ET-1水平明显下降(P〈0.01),CFR及NO的水平明显升高(均为P〈0.05),运动总时间、ST段压低1mm时间明显延长(P〈0.01,P〈0.05)。结论法舒地尔与地尔硫卓均能改善CSX患者的内皮细胞功能,提高患者的运动耐量及CFR,且法舒地尔较地尔硫卓更为有效。 Objective To investigate the therapeutic effects of fasudil and diltiazem on patients with cardiac X-syndrome. Methods Forty-three patients with cardiac X-syndrome were randomly allocated into fasudil treated group (n=24) and diltiazem treated group (n=25) for three months. The clinical presentations, results of treadmill tests, coronary flow reserve (CFR), and the levels of endothelin-l(ET-l) and nitro oxide (NO) were compared before and three months after treatment. Results After the 5-month therapy, chest pain, ST depression and the levels of ET-1 significantly decreased and CFR, the levels of NO significantly increased and total exercise duration, time to 1 mm ST segment depression were significantly longer (P〈0.01 or P〈0.05) in the two groups. Chest pain, ST depression and the levels of ET-1 significantly decreased, CFR and the levels of NO significantly increased(P〈0.05). Total exercise duration and time to 1 mm ST segment depression were significantly longer(P〈 0.05 ) in fasudil group. Conclusion Fasudil has a better effect than diltiazem in the improvement of exercise tolerance for the patients with cardiac X-syndrome.
出处 《中国心血管病研究》 CAS 2010年第4期258-260,共3页 Chinese Journal of Cardiovascular Research
关键词 法舒地尔 地尔硫卓 心脏X综合征 冠状动脉血流储备 Fasudil Dihiazem Cardiac X-syndrome Coronary flow reserve (CFR)
  • 相关文献

参考文献2

二级参考文献8

  • 1[1]MA CS,GAI LY,ZHANG KJ,et al. Intervention Cardiology.Beijing: Publishing House of People's Health,1998∶385-336.
  • 2[2]ACC/AHA Task Force.Guidelines for percutaneous transluminal coronary angioplasty.A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures(Subcommittee on Percutaneous Transluminal Coronary Angioplasty).J Am Coll Cardiol 1988;12∶529.
  • 3[3]Cardiovascular Committee of Chinese Association of the Integration of Traditional and Western Medicine.Criteria for TCM Syndrome differentiation of coronary heart disease.Chin J of Integr Tradi West Med (Chin) 1991;11(5)∶257.
  • 4[4]The Committee of Promoting Blood Circulation to Remove Stasis,China Association of the Integration of Traditional and Western Medicine.Criteria for diagnosis of blood stasis syndrome. Chin J of Integr Tradi West Med(Chin) 1987;7(3)∶129.
  • 5[5]XU XL,GUO YJ,CHEN DM. Atlas of coronary artery disease(Williams MJ edit.).Tianjin: Tianjin Science and Technology Translation Publishing Co.,2001∶44.
  • 6Cannon RO.Mirovascular angina[].The Medical Clinics of North America.1991
  • 7Kaski JC,Cox ID,Crook JR,et al.Diffferential plasma endothelin levels in subgroups of patients with angina and angiographically normal coronary arteries[].American Heart Journal.1998
  • 8Bellamy MF,Goodfellow J,Tweddel AC,et al.Syndrome X and endothelial dysfunction[].Cardiovascular Research.1998

共引文献29

同被引文献33

  • 1张曼,屈晨,曾定尹.Rho/Rho激酶在压力负荷心力衰竭大鼠心肌组织的表达[J].中华心血管病杂志,2005,33(1):73-76. 被引量:52
  • 2周燕,田磊,莫宁.三七总皂苷抗心肌肥大的作用与其影响神经体液因素的关系[J].中国中药杂志,2005,30(12):916-919. 被引量:9
  • 3陈浩.36例心血管X综合征临床分析[J].临床医学,2005,25(11):24-25. 被引量:11
  • 4张曼,佟浩,王文刚,张景轩,卜秀梅,曾定尹.法舒地尔对心力衰竭大鼠心室重塑干预与Rho GTPases活性的作用[J].中国新药与临床杂志,2007,26(9):671-674. 被引量:8
  • 5Leung T, Manser E, Tan L, et al. A novel serine/threonine ki- nas binding the ras-related RhoA GTPase which translocates the kinase toperipheral. J Biol Chem, 1995,270:29051-29054.
  • 6Shibuya M, Suzuki Y, Sugita K, et al. Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage. Aeta Neurochir, 1990,107 : 1 l- 15.
  • 7Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cere- bral vasospasm after aneurysmal subarachnoid hemorrhage. Re- suits of a prospective placebo-controlled double-blind trial. J Neurosurz, 1992,76 : 571-577.
  • 8Shimokawa H, Hiramori K, Iinuma H, et al. Antianginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina : a muhicenter study. J Cardiovasc Pharmacol, 2002,39 : 319-327.
  • 9Vicari RM, Smith WB, Chaitman B, et al. A randomized, dou- ble-blind, placebo-controlled, Phase 2 study: the efficacy of fa- sudil in patients with stable angina. Eur Heart J, 2004,25:138.
  • 10Shimokawa H. Long-term inhibition of Rho-kinaseinduces a re- gression of arterioscleroticcoronary lesions in a porcine model in vivo. Cardiovas Res,2001,51 : 169-177.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部